
    
      In this study, patients will be recruited and randomized in a ratio of 2:2:1 into Fugan bid
      group (Fugan AM + Fugan PM), Fugan qd group (Fugan AM + Placebo PM), and placebo group
      (Placebo AM + Placebo PM). Randomization will be stratified by disease severity (mild IGA=2
      vs. moderate IGA=3).

      The patients will be given 3-week treatment and followed up for two weeks after the
      treatment.

      Screening period is set as 1 week. Subjects will be given 3-week treatment and followed up
      for two weeks after the treatment.

      Approximately 310 subjects will be randomized to achieve 250 evaluable subjects completing
      the study.
    
  